Targeted drugs in spondyloarthritis during pregnancy and lactation.
Pharmacol Res
; 136: 21-28, 2018 10.
Article
em En
| MEDLINE
| ID: mdl-30125669
ABSTRACT
Spondyloarthritis (SpA) are a heterogeneous group of chronic inflammatory joint diseases that includes several clinical subgroups. SpA can affect women in the reproductive stage so pregnancy can influence the course of the disease and SpA can affect the maternal-fetal outcome. The treatment of SpA has changed dramatically in recent years and the use of targeted drugs is part of therapeutic armamentarium. The use of targeted drugs during pregnancy is controversial because the information available on safety during this period is still limited. Several cytokines have an important role in the normal development of pregnancy or other cytokines may play a role in certain maternal-fetal complications. Potentially targeted drugs can affect the function of these cytokines during pregnancy. The aim of this study is to review the interrelationship between SpA during pregnancy and lactation, the role of some cytokines during normal pregnancy and the development of maternal-fetal complications as well as to review recent information on targeted drugs during pregnancy and breastfeeding in these patients in order to maximize their use in these critical periods of life.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Espondilartrite
/
Terapia de Alvo Molecular
Limite:
Animals
/
Female
/
Humans
/
Pregnancy
Idioma:
En
Revista:
Pharmacol Res
Assunto da revista:
FARMACOLOGIA
Ano de publicação:
2018
Tipo de documento:
Article